Table 2.

Studies of monoclonal antibodies in solid organ transplant patients

Study	Population	Monoclonal Antibody	Outcomes
Yetmar et al.69	73 patients with lung, liver, kidney, and heart transplant	Bamlanivimab	1.12.3% of patients required hospitalization for median of 4 d. 2.No deaths
Klein et al.70	20 of 95 kidney transplant patients	Balmanivimab	1.mAb administration led to 15% vs 76% emergency department/hospital visits (P < .001).
Del Bello et al.71	16/48 patients with kidney, kidney-liver, kidney-heart	5 bamlanivimab 9 bamlanivimab + etesevimab 2 casirivimab + imdevimab	1.0 vs 46% patients developed severe respiratory failure in the non-mAb group (P = .007).
Jenks et al.72	175/617 high-risk patients	83% received bamlanivimab + etesevimab 16% bamlanivimab	1.7% vs 24% hospitalizations and 0 vs 2.7% deaths in mAb vs non-mAb groups, respectively

^aBamlanivimab or bamlanivimab + etesevimab research are presented for context, but these drugs no longer may be appropriate, depending on circulating variants of concern.